Most Active Volume Stock: Opko Health, Inc. (NASDAQ:OPK)


Opko Health, Inc. (NASDAQ:OPK) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Opko Health, Inc. (NASDAQ:OPK) gained 5.72 Percent and closed its previous trading session at $4.99. The stock traded with the average Volume of 4.82 Million at the end of last session.

The company reported its last earnings Actual EPS of $-0.32/share. While, the analyst predicted that the company could provide an EPS of $-0.08/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.24/share which shows an Earnings Surprise of -300 Percent.

Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Opko Health, Inc. (NASDAQ:OPK) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 44.01% where SMA50 and SMA200 are 49.88% and 0.36% respectively.

The company shows its Return on Assets (ROA) value of -12%. The Return on Equity (ROE) value stands at -16.3%. While it’s Return on Investment (ROI) value is -10.8%.

Opko Health, Inc. (NASDAQ:OPK) currently has a Weekly Volatility of 6.91% percent while its Monthly Volatility is at 5.81% percent. While talking about Performance of the Stock, Opko Health, Inc. currently has a Weekly performance of 19.95%, monthly performance percentage is 60.45 percent, Quarterly performance is 26.97 percent, 6 months performance shows a percent value of -5.13% and Yearly Performance is -24.39 percent.

Company Profile:

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.